IMUX Relative Valuation
IMUX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMUX is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for IMUX's competitors is 13.87, providing a benchmark for relative valuation. Immunic Inc Corp (IMUX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
ORCL
Oracle Corp
160.320
USD
+0.01%
TSLA
Tesla Inc
344.300
USD
+0.14%
MSFT
Microsoft Corp
456.930
USD
-0.27%
META
Meta Platforms Inc
644.960
USD
+1.23%
NVDA
NVIDIA Corp
135.780
USD
+1.04%
AVGO
Broadcom Inc
234.390
USD
+1.17%
WMT
Walmart Inc
97.180
USD
-0.63%
AAPL
Apple Inc
206.330
USD
-0.26%
AMZN
Amazon.com Inc
202.750
USD
-0.65%
XOM
Exxon Mobil Corp
104.530
USD
-0.40%
FAQ
Is Immunic Inc (IMUX) currently overvalued or undervalued?
Immunic Inc (IMUX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1204.83. The fair price of Immunic Inc (IMUX) is between to according to relative valuation methord.
What is Immunic Inc (IMUX) fair value?
How does IMUX's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunic Inc (IMUX) as of May 21 2025?
What is the current FCF Yield for Immunic Inc (IMUX) as of May 21 2025?
What is the current Forward P/E ratio for Immunic Inc (IMUX) as of May 21 2025?